Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe

SIMPLE SUMMARY: Multiple treatment regimens are approved for relapsed/refractory multiple myeloma (RRMM), but evidence of their real-world use is limited. This study included 701 patients across 11 countries in Europe and Israel between March 2017 and March 2020, and examined the real-world use of c...

Descripción completa

Detalles Bibliográficos
Autores principales: Terpos, Evangelos, Zambello, Renato, Leleu, Xavier, Kuehr, Thomas, Badelita, Sorina N., Katodritou, Eirini, Brescianini, Alessandra, Liang, Tony, Wetten, Sally, Caers, Jo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657308/
https://www.ncbi.nlm.nih.gov/pubmed/36358731
http://dx.doi.org/10.3390/cancers14215311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657308/
https://www.ncbi.nlm.nih.gov/pubmed/36358731
http://dx.doi.org/10.3390/cancers14215311

Ejemplares similares